Improving Therapeutic Adherence With a Co-constructed Program Involving Both Patients and Health Care Professionals

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

450 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-18

Study Completion Date

2025-10-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background Cystic fibrosis is a life-threatening genetic disorder responsible for pulmonary failure and multi-systemic complications involving specific and large medical care burden. To date, no program has shown its effectiveness in improving therapeutic adherence. A new approach to develop a co-constructed program involving patients and professionals may contribute to improve therapeutic adherence.

Objectives The aim of the MUCOBS-Trial project is to create a program to increase therapeutic adherence and to evaluate its efficacy in adult patients with cystic fibrosis in 3 CF centers in France.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience

NCT01013896

Cystic Fibrosis

COMPLETED NA

Improving Adherence and Clinical Outcome in Cystic Fibrosis (CF) Patients

NCT01025258

Cystic Fibrosis

COMPLETED NA

Physical Activity Profile and Sedentary Behaviour in Adults With Cystic Fibrosis

NCT06507956

Cystic Fibrosis

RECRUITING

Cystic Fibrosis Adherence Study

NCT04217889

Cystic Fibrosis

COMPLETED

Tele-Coaching Intervention to Improve Treatment Adherence in Cystic Fibrosis

NCT03921229

Cystic Fibrosis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cystic Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

interventional arm

Group Type EXPERIMENTAL

" Information-Motivation-Behavioral skills " intervention.

Intervention Type OTHER

* "information" -\> Reminders of medication: mobile application
* "Motivation" -\> Coaching by patients: intervention or coaching by an expert patient, animation of a social network of patients
* "Behavioral skills" -\> Accompaniment by professionals: therapeutic education, assessment of membership during medical visits, prioritization of treatments

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

" Information-Motivation-Behavioral skills " intervention.

* "information" -\> Reminders of medication: mobile application
* "Motivation" -\> Coaching by patients: intervention or coaching by an expert patient, animation of a social network of patients
* "Behavioral skills" -\> Accompaniment by professionals: therapeutic education, assessment of membership during medical visits, prioritization of treatments

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with Cystic Fibrosis
* Aged 18 or more
* Speaking / understanding French
* Followed in one of the participating centers (CRCM of the Auvergne-Rhône-Alpes region)
* Resident in Auvergne-Rhône-Alpes
* Affiliated to the general health insurance scheme